FDA — authorised 15 November 2017
- Application: BLA761047
- Marketing authorisation holder: ULTRAGENYX PHARM INC
- Status: approved
FDA authorised Mepsevii on 15 November 2017
Yes. FDA authorised it on 15 November 2017; FDA has authorised it.
ULTRAGENYX PHARM INC holds the US marketing authorisation.